Ocedurenone

Ocedurenone
Clinical data
Other names	KBP-5074
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[(3S,3aR)-3-Cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile;
CAS Number	1359969-24-6;
PubChem CID	75593324;
UNII	L46509378R;
Chemical and physical data
Formula	C28H30ClN5O2
Molar mass	504.03 g·mol−1

Ocedurenone, formerly known as KBP-5074,^[1] is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments.^[2]^[3] In 2023, KPB Biosciences entered into talks to sell the drug to Novo Nordisk for up to USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.^[4]^[5]